In the past week, ALGS stock has gone up by 31.38%, with a monthly gain of 111.97% and a quarterly surge of 440.77%. The volatility ratio for the week is 12.73%, and the volatility levels for the last 30 days are 13.11% for Aligos Therapeutics Inc. The simple moving average for the past 20 days is 34.61% for ALGS’s stock, with a 162.70% simple moving average for the past 200 days.
Is It Worth Investing in Aligos Therapeutics Inc (NASDAQ: ALGS) Right Now?
Company’s 36-month beta value is 2.67.Analysts have differing opinions on the stock, with 1 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ALGS is 2.67M, and currently, short sellers hold a 17.12% ratio of that floaft. The average trading volume of ALGS on December 27, 2024 was 353.68K shares.
ALGS) stock’s latest price update
The stock of Aligos Therapeutics Inc (NASDAQ: ALGS) has increased by 10.24 when compared to last closing price of 39.34.Despite this, the company has seen a gain of 31.38% in its stock price over the last five trading days. globenewswire.com reported 2024-12-13 that SOUTH SAN FRANCISCO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) — Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option to purchase an aggregate of 5,500 shares of the Company’s stock (the “Inducement Grant”) to a newly hired employee on December 10, 2024 (the “Grant Date”), in connection with the commencement of employment.
Analysts’ Opinion of ALGS
Many brokerage firms have already submitted their reports for ALGS stocks, with H.C. Wainwright repeating the rating for ALGS by listing it as a “Buy.” The predicted price for ALGS in the upcoming period, according to H.C. Wainwright is $75 based on the research report published on August 19, 2024 of the current year 2024.
Piper Sandler, on the other hand, stated in their research note that they expect to see ALGS reach a price target of $3, previously predicting the price at $2. The rating they have provided for ALGS stocks is “Overweight” according to the report published on January 06th, 2023.
Jefferies gave a rating of “Buy” to ALGS, setting the target price at $3 in the report published on January 06th of the previous year.
ALGS Trading at 110.52% from the 50-Day Moving Average
After a stumble in the market that brought ALGS to its low price for the period of the last 52 weeks, the company was able to rebound, for now settling with 0.98% of gains for the given period.
Volatility was left at 13.11%, however, over the last 30 days, the volatility rate increased by 12.73%, as shares surge +103.14% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +496.56% upper at present.
During the last 5 trading sessions, ALGS rose by +31.38%, which changed the moving average for the period of 200-days by +99.40% in comparison to the 20-day moving average, which settled at $32.22. In addition, Aligos Therapeutics Inc saw 161.27% in overturn over a single year, with a tendency to cut further gains.
Stock Fundamentals for ALGS
Current profitability levels for the company are sitting at:
- -15.77 for the present operating margin
- 0.66 for the gross margin
The net margin for Aligos Therapeutics Inc stands at -12.83. The total capital return value is set at -1.4. Equity return is now at value -146.69, with -88.31 for asset returns.
Based on Aligos Therapeutics Inc (ALGS), the company’s capital structure generated 0.12 points at debt to capital in total, while cash flow to debt ratio is standing at -12.13.
Currently, EBITDA for the company is -85.06 million with net debt to EBITDA at 0.28. When we switch over and look at the enterprise to sales, we see a ratio of 20.68. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.81.
Conclusion
In a nutshell, Aligos Therapeutics Inc (ALGS) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
